Status
Conditions
Treatments
About
Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.
Full description
Chronic inflammatory skin diseases, despite low mortality, significantly impair quality of life. Up to 80% of dermatological patients experience severe itch and poor sleep, and related such mental health challenges as anxiety and depression. The relationship between skin diseases and mental health highlights the challenges that doctors face in treating these conditions. Existing psychotherapeutics such as Mindfulness training, Cognitive Behavioural Therapy, and Acceptance and Commitment Therapy are widely used and effective in the treatment of mental health illness. However, there is limited evidence on the application of such interventions in dermatology and most mental health apps lack robust clinical evaluation. We report the design of a randomised controlled trial to evaluate the efficacy and implementation of a mobile app containing dermatology-specified psychotherapeutic strategies in reducing QoL burden.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)
Patients with unstable psychiatric condition, characterized by
o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months
Patients with unstable dermatological condition, characterized by
Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR
Any of the following within 3 months
Primary purpose
Allocation
Interventional model
Masking
690 participants in 2 patient groups
Loading...
Central trial contact
Ellie Choi, MBBS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal